Strategies for management of patients with, or at risk for, medication-related osteonecrosis of
the jaw (MRONJ) were set forth in the American Association of Oral and Maxillofacial …

The aim of this systematic review was to answer the question: What are the treatments
available for bisphosphonate-related osteonecrosis of the jaws (BRONJ) and their …

PURPOSE To provide guidance regarding best practices in the prevention and
management of medication-related osteonecrosis of the jaw (MRONJ) in patients with …

Context Antiresorptive therapy significantly reduces fracture risk in patients with benign bone
disease and skeletal-related events (SREs) in patients with bone metastases (BM) …

Medication‐related osteonecrosis of the jaw (MRONJ) is an adverse event that may inhibit
the treatment of primary disease and remarkably influence the patient's quality of life. The …

Osteonecrosis of the jaws (ONJ) is an adverse side event of bisphosphonates and
denosumab, antiresorptive agents that effectively reduce the incidence of skeletal-related …

The medication-related osteonecrosis of the jaw (MRONJ) is believed to be a therapy-
resistant entity. Although the application of the recommended conservative and surgical …

Background Bisphosphonate drugs can be used to prevent and treat osteoporosis and to
reduce symptoms and complications of metastatic bone disease; however, they are …

Background Medication-related osteonecrosis of the jaw (MRONJ) is a serious complication
associated with antiresorptive and antiangiogenic medications, of which impaired …

Management of osteonecrosis of the jaw associated with antiresorptive agents is
challenging, and outcomes are unpredictable. The severity of disease is the main guide to …